Close Menu

Quidel

NEW YORK (GenomeWeb News) – Quidel reported after the close of the market on Wednesday that second-quarter revenues rose 12 percent year over year.

This article has been corrected from a previous version that stated that Axxin disclosed in January that it is developing the NAT analyzer and iNAT platforms. In fact, Alere disclosed that it is developing these platforms.

Quidel President and CEO Doug Bryant said this week that the company expects to complete clinical trials by the end of the current quarter to support a subsequent application for US regulatory approval of its AmpliVue C.

NEW YORK (GenomeWeb News) – Quidel reported after the close of the market Wednesday that its first-quarter revenues fell 36 percent as a weak cold and flu season hit the firm's sales.

Roche last week said that it has received US Food and Drug Administration approval of a new pre-analytical instrument that integrates primary tube handling into its Cobas molecular testing platform.

Quidel said this week that it has received the CE mark for its AmpliVue C. difficile assay, making it the first commercially available test using Quidel's non-instrumented format.

Quidel said today that it has received 510(k) clearance from the US Food and Drug Administration for its Quidel Molecular Influenza A+B assay for use with the Cepheid SmartCycler PCR system.

Pages

The US has sent its formal notice of withdrawal from the World Health Organization, according to the Wall Street Journal.

Science reports that a draft spending bill would increase the US National Institutes of Health budget by 13 percent.

The Harvard Crimson reports that Harvard and MIT are suing the Department of Homeland Security and ICE over the new international student visa policy.

In Nucleic Acids Research this week: algorithm to determine molecular sequence types and other microbial features, computational method to uncover R-loop structures, and more.